Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

- Millennium on track to file sNDA in first quarter 2008 -

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the interim analysis results of the large, international Phase III VISTA(1) trial in patients with newly diagnosed multiple myeloma showed that the therapy of VELCADE, melphalan and prednisone (VMP) demonstrated a highly statistically significant improvement in all efficacy measures, including time-to-disease progression, complete remission rate, progression-free survival and overall survival, compared to melphalan and prednisone (MP) alone. Based on the recommendation of an independent data monitoring committee (IDMC), which conducted the planned interim, the control arm of the trial was stopped early to allow patients still being treated with MP to have VELCADE added to their therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"These results position VELCADE based therapy as a new standard of care for newly diagnosed multiple myeloma patients," said Paul Richardson, M.D., Associate Professor of Medicine, Harvard Medical School; Clinical Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Boston; and a lead investigator of the VISTA trial. "The combination of VELCADE with melphalan and prednisone surpassed all efficacy endpoints, including time-to-disease progression, complete remission rate, progression-free survival and overall survival, and did so, much earlier than expected. We are excited at the possibility this new therapy could be available to our patients sooner."

In the first
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... a conference call and audio webcast to discuss financial results ... closes on Thursday, July 31, 2014 at 4:30 p.m. ET. ... Date: July 31, 2014 Time: 4:30 PM ET ... International: (678) 373-0875 A webcast replay will be ...
(Date:7/28/2014)... Calif., July 28, 2014 Anthera Pharmaceuticals, Inc. (NASDAQ: ... update for the second quarter ended June 30, 2014. ... 30, 2014 was $7.3 million, compared to $8.3 million for ... is a direct result of a decrease in interest expense ... the six months ended June 30, 2014 was $15.2 million, ...
(Date:7/28/2014)... Corporation (NASDAQ: LMNX ) today announced financial ... Financial and operating highlights include the following: ... 2 percent increase over the second quarter of 2013. ... a 9 percent increase over the second quarter of ... analyzers, which included 148 LX systems, 96 MAGPIX systems, ...
Breaking Medicine Technology:Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7Luminex Corporation Reports Second Quarter 2014 results 2Luminex Corporation Reports Second Quarter 2014 results 3Luminex Corporation Reports Second Quarter 2014 results 4Luminex Corporation Reports Second Quarter 2014 results 5Luminex Corporation Reports Second Quarter 2014 results 6Luminex Corporation Reports Second Quarter 2014 results 7Luminex Corporation Reports Second Quarter 2014 results 8Luminex Corporation Reports Second Quarter 2014 results 9Luminex Corporation Reports Second Quarter 2014 results 10Luminex Corporation Reports Second Quarter 2014 results 11Luminex Corporation Reports Second Quarter 2014 results 12Luminex Corporation Reports Second Quarter 2014 results 13Luminex Corporation Reports Second Quarter 2014 results 14Luminex Corporation Reports Second Quarter 2014 results 15Luminex Corporation Reports Second Quarter 2014 results 16Luminex Corporation Reports Second Quarter 2014 results 17
... PRGO ; TASE) today announced results for its ... and CEO Joseph C. Papa commented, "We are very pleased ... contributors to this strong performance were $44 million of new ... segments and another solid quarter in Nutritionals. In Consumer Healthcare, ...
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today ... at the Bank of America Merrill Lynch Healthcare conference in Las ... Vegas, NV Presentation date: Tuesday May 10, 2011 ... A live webcast and 30-day archive of this presentation will ...
Cached Medicine Technology:Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 2Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 3Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 4Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 5Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 6Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 7Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 8Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 9Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 10Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 11Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 12Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 13Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 14Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 15Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 16Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 17Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 18
(Date:7/28/2014)... Cancer cells are gluttons. We have long known that ... became clear that some tumor cells are also characterized ... unlikeliness to join in an ordered set. Researchers are ... metastasis. , At EPFL, Etienne Meylan,s research team was ... for sugar and mesenchymal behavior result from the ...
(Date:7/28/2014)... Ticket Down is a reputable source ... between Manchester City and Liverpool FC at Yankee Stadium ... countless big events since it opened several years ago. It ... Yankee Stadium, however, it has been a popular destination for ... , The Yankees Stadium is the home of the ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A January ... reduction of gluten intake in those who were self-diagnosed ... Mittry, director of nutrition for San Diego health and ... various gluten considerations for those who are unclear about ... explains that gluten is a protein, found in wheat, ...
(Date:7/28/2014)... 2014 Dawn Echols’ professional background ... and music. This experience has honed her people ... psychology. Her professional counseling ( http://dawningphoenix.com ) work ... for offenders in domestic violence. , As ... she enjoys counseling individuals and groups for a ...
(Date:7/28/2014)... Ticket Down is reliable source ... Dallas, TX at the Cotton Bowl. The 2014 Guinness ... and it is an eight team tourney. The tournament ... teams from La Liga, Serie A, English Premier League, and ... out on the pitch include: Manchester United, Manchester City, ...
Breaking Medicine News(10 mins):Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 3Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3
... increase lowers chance of hospitalization or death , ... heart failure, high doses of the drug losartan, an ... and death, a new study shows. , Though ARBs ... study focused on whether dose level makes a difference. ...
... what women should do about the new guidelines, , WEDNESDAY, ... force recommended that women wait until they,re 50 to get ... swift. , Critics such as the American Cancer Society vowed ... age 40 for women of average risk. The American ...
... ... the AnnArbor.com Business Review awarded the company top honors in the Healthcare category during ... ongoing commitment to the local community and recent completion of a $3.6 million expansion ... ...
... Apieron, Inc. has asked the court presiding over ... to raise additional grounds for invalidating Aerocrine,s broadest patent ... , In its motion, Apieron alleges that recently obtained ... Alving, Jan Lundberg, and Edward Weitzberg, inventors named on ...
... , SYDNEY, Nov. 18 Members of the Church ... Ambassadors were out in force Sunday, November 15, distributing thousands ... purpose: to inform kids of the truth about drugs so ... a new drug called Mephedrone, or "MM-Cat," that Sydney students ...
... ... a KTRK-TV, a local television news affiliate, is bringing to light a new technique ... the recovery process and the aesthetic results for patients who undergo surgical treatment for ... ...
Cached Medicine News:Health News:Heart Failure Drug May Help More in Higher Doses 2Health News:Mammography: What to Do Now? 2Health News:Mammography: What to Do Now? 3Health News:Mammography: What to Do Now? 4Health News:Terumo Heart, Inc. Wins Top Healthcare Category Honors at AnnArbor.com's 5th Annual ‘Deals Of The Year' Award Ceremony 2Health News:Terumo Heart, Inc. Wins Top Healthcare Category Honors at AnnArbor.com's 5th Annual ‘Deals Of The Year' Award Ceremony 3Health News:Scientology Volunteers Attack Drug Abuse in Sydney 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: